Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

terminated133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_3

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

NCT04745832
withdrawnphase_1

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

NCT05604417
withdrawnphase_2

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

NCT05209308

Clinical Trials (3)

Showing 3 of 3 trials
NCT04745832Phase 3

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Terminated
NCT05604417Phase 1

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Withdrawn
NCT05209308Phase 2

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3